Meet The Team How-Tos Our Supporters How to Participate in Precision Panc Membership Meeting Minutes Remit of Steering Committee Patient Stories Documents Working with the NHS Patient Public Engagement Meetings Governance News Clinicians Area Clinical Trials What is precision medicine? Information and Support What is Pancreatic Cancer? Current Research Our Researchers Privacy Policy Patients and Carers Contact Us About us Home
Patient 600 recruited Precision-Panc Enters 500th patient to platform Professor Andrew Biankin – it’s about time Pancreatic Cancer is debated in the Scottish Parliament Please watch this very moving video from NIHR West of England Exciting week for the Precision-Panc project Glasgow to host Pancreatic Symposium – Friday 21st May 2021 Survey on the impact of COVID-19 pandemic on pancreatic cancer research Precision-Panc in the Press Precision-Panc / PRIMUS 002 Opens a new site Precision-Panc Re-opens to Recruitment Information on COVID-19 and Pancreatic Cancer from PCUK Precision-Panc and PRIMUS studies suspended to recruitment Precision-Panc Recruits Patient 300 Paul Taylor tells us about his Precision-Panc experience Precision-Panc help raise funds for Pancreatic Cancer Scotland Precision-Panc Recruits Patient 250 Marking World Pancreatic Cancer Day Precision-Panc working with myTomorrows Precision-Panc Roundtable Final Report New Glasgow Cancer Assays by GPOL and Agilent Technologies Precision-Panc opens site 25! Precision-Panc Summer Newsletter Precision-Panc Recruits Patient 200! Precision-Panc Brochure Royal Bournemouth Hospital Opens Finding the right treatment for the patient CRUK animate the Precision-Panc platform CRUK / Precision-Panc Video Professor Biankin receives the Order of Australia in Queen’s Birthday Honours Precision-Panc opens its 20th Site Precision Panc Spring Newsletter Precision-Panc Opens Site 19 Recent Media Pieces Regarding 100 Patient Milestone Site 17 opens for Precision-Panc PRIMUS 002 opens Informing the Future of Genomic Medicine in Scotland Report is Published St James’s University Hospital Opens Precision-Panc Opens its 15th site Glasgow Experts Lead UK Pancreatic Cancer Research 11th site opens to PRECISION-Panc Scotsman Conferences Blogspot November is Pancreatic Cancer Awareness Month First Precision-Panc Trial Opens In Glasgow Cancer Research UK Investment Landscape of pancreatic neuroendocrine cancer Whole Genome Sequencing from EUS biopsies Upcoming Pancreas 2016 Conference Scottish Genome Partnership Announced Identification of four Pancreatic Cancer subtypes offers new treatment insight into the disease First Minister announces £4m ‘Precision Medicine Ecosystem’
Home | News | Whole Genome Sequencing from EUS biopsies

Whole Genome Sequencing from EUS biopsies

Published: 5th July 2016

Cancer can be described as a genetic disease – we can say this because cancer generally arises when a person’s genome becomes corrupted and the cells in their body stop behaving precisely as they should.   Scientists and clinicians are working together to develop treatment strategies based on the genetic makeup of each patient’s individual cancer.

Recently, our understanding of the genetic and molecular events that lead to pancreatic cancer has increased dramatically.  However, a major obstacle preventing us from unravelling the pancreatic cancer genome, has been our inability to obtain enough of the cancer tissue needed for the tests.

In the main, scientists and clinicians rely on surgically removed pancreatic tissue for genetic tests. However, since the pancreas is positioned amongst other major organs in the body, it needs major invasive surgery to access it and the reality is that only a minority of patients (< 20%) are able to undergo surgery for pancreatic cancer at the time of diagnosis.  This means that it is almost impossible to easily obtain tissue for testing. Therefore, new techniques to obtain good quality genetic data from patients are urgently sought to improve our treatment of the disease.

Scientists and surgeons within our organisation have used a procedure called endoscopic ultrasound (EUS) – a standard diagnostic procedure used in most clinical pancreatic units – to obtain biopsies specifically for genetic testing.  Using tissue obtained from such EUS biopsies, our team developed a technique to successfully generate whole genome sequencing (WGS) data which they then analysed to identify the possible changes in the genome responsible for the development of cancer in that patient.

Our team has confirmed that it is possible to perform WGS from these small biopsies, and is likely to be successful in most patients with pancreatic cancer. This could potentially allow patients to have sophisticated genetic tests carried out on their cancer, which could help select the most appropriate experimental treatment in the form of clinical trials. This will further allow scientists greater insight into the processes that cause this disease and how it develops over time,especially once patients receive chemotherapy.

© 2024 Precision Panc
Web design by Creatomatic
This site uses cookies.
Read our privacy policy

This site uses cookies for marketing, personalisation, and analysis purposes. You can opt out of this at any time or view our full privacy policy for more information.